

# Comparative Financials

**2024**



# Comparative Financial Reporting

Lonza has announced that its new simplified and streamlined operating model became effective on 1 April 2025. The simplified One Lonza organization comprises three newly-formed CDMO Business Platforms which manage multiple technology platforms:

- Integrated Biologics comprises the Mammalian and Drug Product Services technologies<sup>1</sup>
- Advanced Synthesis comprises the Small Molecules and Bioconjugates technologies
- Specialized Modalities includes the Cell & Gene, mRNA, Microbial technologies, and Bioscience products

The Capsules & Health Ingredients business continues to operate in its existing structure.

Today Lonza publishes its updated financials for 2024 based on the One Lonza organization, providing investors with comparable figures for the Half-Year 2025 reporting on 23 July 2025 and the Full-Year 2025 reporting.

<sup>1</sup> Integrated Biologics also includes Lonza's Licensing business

# Comparative Full-Year 2024 Financial Information as of 31 December 2024

## Updated Full-Year 2024

Million CHF	Integrated Biologics	Advanced Synthesis	Specialized Modalities	Capsules & Health Ingredients	Corporate	Total Group
Net Sales	2,883	1,366	1,099	1,054	172	6,574
CORE EBITDA	1,045	488	192	256	(73)	1,908
Margin in %	36.2	35.7	17.5	24.3	n.a.	29.0
Capital Expenditures (CapEx)	607	280	262	89	179	1,417

## Reported Full-Year 2024

Million CHF	Biologics <sup>1</sup>	Small Molecules	Cell & Gene <sup>2</sup>	Capsules & Health Ingredients	Corporate	Total Group
Net Sales	3,676	983	689	1,054	172	6,574
CORE EBITDA	1,266	351	108	256	(73)	1,908
Margin in %	34.4	35.7	15.7	24.3	n.a.	29.0
Capital Expenditures (CapEx)	828	129	192	89	179	1,417

<sup>1</sup> Former Biologics division comprised Mammalian, Drug Product Services, Bioconjugates, Microbial, Licensing and mRNA

<sup>2</sup> Former Cell & Gene division comprised Cell & Gene Technologies and Bioscience

# Comparative Half-Year 2024 Financial Information as of 30 June 2024

## Updated Half-Year 2024

Million CHF	Integrated Biologics	Advanced Synthesis	Specialized Modalities	Capsules & Health Ingredients	Corporate	Total Group
Net Sales	1,337	575	530	540	75	3,057
CORE EBITDA	475	192	124	134	(32)	893
Margin in %	35.5	33.4	23.4	24.8	n.a.	29.2
Capital Expenditures (CapEx)	288	129	87	28	90	622

## Reported Half-Year 2024

Million CHF	Biologics <sup>1</sup>	Small Molecules	Cell & Gene <sup>2</sup>	Capsules & Health Ingredients	Corporate	Total Group
Net Sales	1,709	402	331	540	75	3,057
CORE EBITDA	594	135	62	134	(32)	893
Margin in %	34.8	33.6	18.7	24.8	n.a.	29.2
Capital Expenditures (CapEx)	387	60	57	28	90	622

<sup>1</sup> Former Biologics division comprised Mammalian, Drug Product Services, Bioconjugates, Microbial, Licensing and mRNA

<sup>2</sup> Former Cell & Gene division comprised Cell & Gene Technologies and Bioscience

For publications and further  
information please contact:

**Lonza Group Ltd**

Muenchensteinerstrasse 38  
4002 Basel, Switzerland  
Tel + 41 61 316 81 11  
[www.lonza.com](http://www.lonza.com)

**Investor Relations**

[investor.relations@lonza.com](mailto:investor.relations@lonza.com)

**Media**

[media@lonza.com](mailto:media@lonza.com)

**Share Register**

c/o Computershare Schweiz AG  
P.O. Box  
4601 Olten, Switzerland  
Tel + 41 62 205 77 00  
Fax + 41 62 205 77 90  
[share.register@computershare.ch](mailto:share.register@computershare.ch)

## Disclaimer

Except as otherwise required by law, Lonza disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after this presentation was published.

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

© 2025 Lonza Ltd

**[www.lonza.com](http://www.lonza.com)**